Cholesterol-lowering drug candidates are in the spotlight this week with the FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) meeting Wednesday and Thursday to pass judgment on two of those drugs – lomitapide from Aegerion Pharmaceuticals Inc.; and Kynamro (mipomersen sodium) from Genzyme, a unit of Sanofi SA, a first-in-class second-generation antisense apolipoprotein B synthesis inhibitor, developed by Isis Pharmaceuticals Inc.